Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurence Booth

Showing results (21-30 of 92) with videos related to

Pageof 10
Sort By:
Cellular Signalling|September 15, 2019
Signaling alterations caused by drugs and autophagyPaul Dent, Laurence Booth, Andrew Poklepovic, et al.
Cellular Signalling|February 23, 2020
The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cellsJane L Roberts, Andrew Poklepovic, Laurence Booth, et al.
Frontiers in Oncology|September 28, 2020
GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor SignalingLaurence Booth, Cameron West, Daniel Von Hoff, et al.
Anti-Cancer Drugs|March 11, 2022
Mechanisms of GZ17-6.02 resistanceLaurence Booth, Cameron West, Daniel Von Hoff, et al.
Frontiers in Oncology|May 3, 2021
Corrigendum: GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells <i>via</i> Autophagy and Death Receptor SignalingLaurence Booth, Cameron West, Daniel Von Hoff, et al.
Anti-Cancer Drugs|August 16, 2021
The development of multi-kinase inhibitors as pancreatic cancer therapeuticsPaul Dent, Andrew Poklepovic, Laurence Booth, et al.
Anti-Cancer Drugs|February 27, 2023
A novel combination of isovanillin, curcumin, and harmine (GZ17-6.02) enhances cell death and alters signaling in actinic keratoses cells when compared to individual components and two-component combinationsZachary A Bordeaux, Shawn G Kwatra, Laurence Booth, et al.
Advances in Cancer Research|February 7, 2018
Unconventional Approaches to Modulating the Immunogenicity of Tumor CellsLaurence Booth, Jane L Roberts, John Kirkwood, et al.
Cancer Biology & Therapy|June 21, 2018
Valproate augments Niraparib killing of tumor cellsLaurence Booth, Jane L Roberts, Rumeesa Rais, et al.
Oncotarget|December 2, 2016
PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxideLaurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
Pageof 10

Showing results (21-30 of 92) with videos related to

Sort By:
Pageof 10
Cellular Signalling|September 15, 2019
Signaling alterations caused by drugs and autophagyPaul Dent, Laurence Booth, Andrew Poklepovic, et al.
Cellular Signalling|February 23, 2020
The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cellsJane L Roberts, Andrew Poklepovic, Laurence Booth, et al.
Frontiers in Oncology|September 28, 2020
GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor SignalingLaurence Booth, Cameron West, Daniel Von Hoff, et al.
Anti-Cancer Drugs|March 11, 2022
Mechanisms of GZ17-6.02 resistanceLaurence Booth, Cameron West, Daniel Von Hoff, et al.
Frontiers in Oncology|May 3, 2021
Corrigendum: GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells <i>via</i> Autophagy and Death Receptor SignalingLaurence Booth, Cameron West, Daniel Von Hoff, et al.
Anti-Cancer Drugs|August 16, 2021
The development of multi-kinase inhibitors as pancreatic cancer therapeuticsPaul Dent, Andrew Poklepovic, Laurence Booth, et al.
Anti-Cancer Drugs|February 27, 2023
A novel combination of isovanillin, curcumin, and harmine (GZ17-6.02) enhances cell death and alters signaling in actinic keratoses cells when compared to individual components and two-component combinationsZachary A Bordeaux, Shawn G Kwatra, Laurence Booth, et al.
Advances in Cancer Research|February 7, 2018
Unconventional Approaches to Modulating the Immunogenicity of Tumor CellsLaurence Booth, Jane L Roberts, John Kirkwood, et al.
Cancer Biology & Therapy|June 21, 2018
Valproate augments Niraparib killing of tumor cellsLaurence Booth, Jane L Roberts, Rumeesa Rais, et al.
Oncotarget|December 2, 2016
PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxideLaurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
Pageof 10